Results 31 to 40 of about 144,657 (253)
Immune checkpoint inhibitor myocarditis: a systematic case study
Российский кардиологический журнал, 2020 Myocarditis is a life-threatening complication of immune checkpoint inhibitor therapy. Over the past ten years, drugs in this group have been used in the treatment of a wide range of hematological diseases and solid tumors.
E. A. Kushnareva, O. M. Moiseeva
doaj +1 more source
Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
Frontiers in Immunology, 2022 Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian +5 more
doaj +1 more source
Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
Case Reports in Dermatological Medicine, 2022 Immune checkpoint inhibitors are associated with a spectrum of cutaneous immune-related adverse events. While maculopapular eruptions are the most common cutaneous adverse event, scleroderma can rarely develop.
Jeffrey L. Dobrzynski +2 more
doaj +1 more source
Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
Clinical Medicine Insights: Endocrinology and Diabetes, 2015 Ipilimumab is a monoclonal antibody directed against CTLA4 T-lymphocyte antigen used as cancer therapy. Immune-related adverse events are common side effects and may include hypophysitis-related hypopituitarism. The clinical features of six patients with
Moeber Mahzari +3 more
doaj +2 more sources
Journal of Medical Case Reports, 2018 Background Novel immune checkpoint inhibitors have been often utilized for different types of malignancies as salvage therapy with varying success. One obstacle to immune checkpoint inhibitor use is the higher incidence of immune-mediated side effects ...
Linh Ngo +3 more
doaj +1 more source
Zhongliu Fangzhi Yanjiu, 2021 Objective To systematically evaluate the efficacy and safety of immune checkpoint inhibitors in the treatment of advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC).
SHAN Yujie +5 more
doaj +1 more source
Cardiotoxicity of immune checkpoint inhibitors
ESMO Open, 2017 Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity. Immune checkpoint inhibitors are a novel class of anticancer drugs, distinct from targeted or tumour type-specific therapies.
VARRICCHI, GILDA +7 more
openaire +3 more sources
Negative Immune Checkpoint Inhibitors
PharmaceuticsCheckpoint inhibitors are a modern therapeutic approach for treating various types of cancer, metabolic diseases, and chronic infections. The main goal of this therapy is to specifically unlock the immune system, allowing it to recognize and eliminate cancer cells or pathogens, primarily through the activation of T lymphocytes.
Magda Drewniak-Świtalska +2 more
openaire +4 more sources
Therapeutic Ultrasound-Enhanced Immune Checkpoint Inhibitor Therapy
Frontiers in Physics, 2021 Immune checkpoint inhibitors (ICIs) are designed to reinvigorate antitumor immune responses by interrupting inhibitory signaling pathways and promote the immune-mediated elimination of malignant cells.
Jinyun Yuan +4 more
doaj +1 more source
Respirology Case ReportsSeveral predictive factors of immune checkpoint inhibitor response have been reported, but there has not been sufficient exploration of which patients benefit from immune checkpoint inhibitor rechallenge.
Toshiaki Takakura +7 more
doaj +1 more source